Back to MPT Database

Dual Prevention Pill (DPP) Regimen

A 28-day contraceptive pill regimen that also provides protection against HIV. 21 pills will contain Truvada and EE/LNG; 7 pills will contain Truvada only. API compatibility (TDF/FTC with EE/LNG and excipients) confirmed. Acceptability studies with over-encapsulated Truvada and COC planned in Zimbabwe and South Africa to start in Q1 2021. Prototype development on hold while seeking additional funding.

Development Stage:

Clinical – Phase 4 (Post-marketing) Trial (C4)

Hormonal/Non-Hormonal:

Hormonal

Delivery Route & Method:

Systemic - Pill/Tablet- Oral

Developer:

  • Population Council

Funding:

  • Children’s Investment Fund Foundation (CIFF)
  • National Institutes of Health (NIH)
  • U.S. Agency for International Development (USAID)

Funding Mechanism:

NIH: NIMH R34
USAID: EECO/USAID

Active Ingredient(s):

  • Combined Oral Contraceptive (COC)
  • Emtricitabine (FTC)
  • Ethinyl Estradiol (EE)
  • Levonorgestrel
  • Tenofovir Disoproxil Fumarate (TDF)

Product Indication(s):

  • HIV
  • Pregnancy

Back to MPT Database